Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
N/A N=54 Randomized Prevention

Exercise and PTSD in Older Veterans

Post-traumatic

Bottom Line

View on ClinicalTrials.gov: NCT02295995 ↗
Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Jan 2020
Primary outcome: Primary: Feasibility of Patient Recruitment — 54 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Exercise as an Adjuvant Therapy for Veterans with PTSD (Behavioral)
Age
Adult, Older Adult · 60+ yrs
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
May 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Feasibility of Patient Recruitment		 54 —
PRIMARY
Physical Activity		 365.8; 349.4; 1954.4; 675.3 —
PRIMARY
PTSD Symptoms		 42.97; 41.06; 35.87; 38.19 —
SECONDARY
Aerobic Endurance		 462.1; 465.9; 531.1; 476.0 —

Summary

The purpose of this study is to examine whether posttraumatic stress disorder (PTSD) symptoms impact adherence to a 12-week physical activity program and whether exercise can help improve PTSD symptoms and health outcomes in older Veterans. Veterans over the age of 60 with PTSD were be recruited to participate in a 12-week physical activity program consisting of aerobic and strengthening activities. 54 participants were randomized to an intervention arm (n=36) or usual care wait-list control (n=18).

Eligibility Criteria

Inclusion Criteria

  • Meet diagnostic criteria for current PTSD,
  • live within 50 miles of Durham VA Medical Center (VAMC) and have reliable transportation,
  • registered for care at the Durham VAMC,
  • independently mobile (assistive devices acceptable),
  • speak and write fluent conversational English

Exclusion Criteria

  • Active substance dependence other than nicotine,
  • cognitive impairment, uncontrolled psychotic symptoms,
  • clinical history of cardiovascular disease (CVD) occurring within the past 3 months,
  • uncontrolled hypertension,
  • renal disease or currently receiving dialysis,
  • psychotropic medication initiated within 6 weeks prior to enrollment
  • proliferative retinopathy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02295995). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search